Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-03-14
2000-02-29
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514269, A61K 31505
Patent
active
06030975&
ABSTRACT:
This invention provides a method for treating cancer in an individual, wherein the cancer is a tumor in which endothelin is upregulated (e.g. tumors of the prostate, lung, liver, breast, brain, stomach, colon, endometrium, testicle, thyroid, pituatary, bladder, kidney, pancreas and meninges) by administering to the individual an effective amount of a compound of Formula I or Formula Ia, as describe herein.
REFERENCES:
patent: 5382569 (1995-01-01), Cody et al.
patent: 5480868 (1996-01-01), Kamei et al.
patent: 5550110 (1996-08-01), Cody et al.
patent: 5840722 (1998-11-01), Baumann et al.
Kobayashi,S., et al., "Localization of endothelin receptors in the human prostate," J. of Urol., 151:763-766 (Mar. 1994).
Nelson,J.B., et al., "Endothelin-1 is expressed in advanced prostate cancer: ET-A receptor mediated proliferation accompanies decreased ET-B receptor expression," 91.sup.st Annual Meeting of the Amer. Urol. Assoc., Orlando, FL, May 4-9, 1996. J. Urol. 155 (May 1996 Suppl.), p. 602A, Abstract #1164.
Yohn,J.J., et al., "Human melanoma cells express functional endothelin-1 receptors," Biochem. & Biophys. Research Communications, 201(1):449-457 (May 30, 1994).
Pagotto,U., et al., "Expression and localization of endothelin-1 and endothelin receptors in human meningiomas: Evidence for a role in tumoral growth," J. Clin. Invest., 96(4):2017-2025 (Oct. 1995).
Kitagawa,N., et al., "A selective endothelin ET.sub.A antagonist, BQ-123, inhibits .sup.125 I-endothelin-1 (.sup.125 I-ET-1) binding to human meningiomas and antagonizes ET-1-induced proliferation of meningioma cells," Cellular and Molecular Neurobiol, 14(2):105-118 (Apr. 1994).
Inagaki,H., et al., "Autoradiographic localization of endothelin-1 binding sites in human colonic cancer tissue," J. Pathol., 168(3):263-267 (Nov. 1992).
Kondo,S., et al., "Endothelin receptor density in human hypertrophic and non-hypertrophic prostate tissue," Tohoku J. Exp. Med. (Japan) 172(4):381-384 (Apr. 1994).
Nelson,J.B., et al., "Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer," Cancer Research, 56(4):663-668 (Feb. 15, 1996).
Moldovan,F., et al., "Human prostate carcinoma and endothelin-1 receptors," International Conf. On Androgenic Hormones, Prostate Cancer, and Benign Prostatic Hyperplasia, New Orleans, LA, Mar. 13-15, 1995. Prostate O (Suppl. 6, 1996), p. 97, Abstract #22.
Nelson,J.B., et al., "Endothelin: A mitogen produced by prostate cancer under androgenic and cytokine regulation circulates in advanced prostate cancer patients," 86.sup.th Annual Mtg. of the Amer. Assoc. for Cancer Research, Toronto, Ontario, Canada, Mar. 18-22, 1995. Proceedings of the Amer. Assoc. for Cancer Res. Annual Mtg. 36(0), 1995, Abstract #226.
Nelson,J.B., et al., "Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate," Nature Medicine, 1(9):944-949 (Sep. 1995).
Riechers, H., et al., "Discovery and Optimization of a Novel Class of Orally Active Nonpeptidic Endothelin-A Receptor Antagonists," J. Med. Chem., 39(11):2123-2128 (May 1996).
BASF - Aktiengesellschaft
Goldberg Jerome D.
LandOfFree
Carboxylic acid derivatives, their preparation and use in treati does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carboxylic acid derivatives, their preparation and use in treati, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carboxylic acid derivatives, their preparation and use in treati will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-683287